Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516805 | 0.85 | ALDH1A1 (0.69) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30618855 | 0.84 | LMNA (0.64) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL298766 | 0.84 | LMNA (0.64) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27923706 | 0.84 | NPSR1 (0.70) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31530440 | 0.83 | LMNA (0.48) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11299077 | 0.83 | LMNA (0.48) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20179255 | 0.83 | LMNA (0.49) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6033685 | 0.81 | HTT (0.63) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1200720 | 0.81 | LMNA (0.74) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10212063 | 0.81 | ALDH1A1 (0.46) | LMNAALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1882375-A | treatment of amyloid-and epileptogenesis-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-12-20 | — | — | CN | disclosed |
| EP-1635909-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | Neurochem (International) Limited (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000406-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-01-06 | — | — | WO | disclosed |
| CN-86103027-A | Electrolyte or the improvement relevant with electrolyte | — | 1986-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | APP, PSEN1, PSEN2 | LMNA 1292/4885ALDH1A1 1493/4885CYP1A2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.